In the podcast episode, panelists delve into the shifting landscape of diagnosing and treating F2/3 MASH patients using non-invasive tests (NITs). They discuss challenges with current diagnostic tools, upcoming blood-based tests, and the potential impact of new drugs like resmetirom and GLP-1s on treatment strategies, aiming to optimize changes in the industry once a drug is approved.
As the episode comes to an end, the group winds up focusing on the need for better, more frequent MASH education as a pivotal need if we are to flatten the growth curve of the MASLD pandemic. In the process, the discussion returns to the risk for women and the important role they can play.
Zobair Younossi and the Surfers, including Global NASH Council member Jörn Schattenberg, discuss Zobair’s work through the Global NASH Council and some implications for low SDI vs. high SDI countries.
Zobair Younossi and Louise Campbell lead a discussion that focuses first on slowing the growth of the MASLD pandemic, then on issues specific to menopausal women
Zobair Younossi joins the Surfers to discuss cost and cost effectiveness, including both how it is measured and how stakeholders might think about it, in the context of the MASLD disease burden.
Global NASH Council Chair Zobair Younossi joins the Surfers to discuss his recent review article on MASLD epidemiology and what stakeholders can do to help stem the tsunami of new patients.
Global Liver Institute Founder and CEO Donna Cryer joins Louise Campbell and Roger Green to discuss her personal challenges during the last part of 2023, the growing strength of the Global Liver Institute and the challenges facing GLI and the entire community in 2024.
Hepatology researcher, key opinion leader and 2023 UEG Rising Star of the Year Hannes Hagstrom joins Louise Campbell and Roger Green in a far-ranging discussion focusing largely on issues in diagnostics and clinical care pathways.
Hepatology researcher and Key Opinion Leader Naim Alkhouri joins Louise Campbell and Roger Green to discuss advances in drug development and NITs and to share thoughts about efficacious use of clinical care pathways.
Patient advocates Mike Betel and Tony Villiotti join Jörn Schattenberg and Roger Green to discuss key events in MASLD 2023 from a patient point of view.
